CRISPR–Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics
Authors:
- Adrianna RutkowskaARAdrianna Rutkowska
- Tadeusz StrózikTSTadeusz Strózik
- Tomasz WasiakTWTomasz Wasiak
- Damian CiunowiczDCDamian Ciunowicz
- Natalia KapelanNKNatalia Kapelan
- Natalia SzczepaniakNatalia Szczepaniak
- Juliusz SosnowskiJSJuliusz Sosnowski
- Weronika GoślińskaWGWeronika Goślińska
- Jakub BartkowiakJBJakub Bartkowiak
- Agata Budny-LewandowskaABAgata Budny-Lewandowska
- Patrycja AntończykPAPatrycja Antończyk
- Maria MarkiewiczMMMaria Markiewicz
Open Access
Abstract
CRISPR–Cas9 has progressed from an experimental tool to a therapeutic modality, marked by the first regulatory approvals of an ex vivo-edited autologous CD34+ hematopoietic stem cell product that induces fetal hemoglobin (CASGEVY/exa-cel). In this narrative review, we synthesize modality-specific molecular diagnostic strategies used across early CRISPR clinical translation. In parallel, early clinical experience has begun to demonstrate the feasibility of in vivo editing, including subretinal delivery for CEP290-associated inherited retinal degeneration (EDIT-101 programme) and hepatocyte-targeted lipid nanoparticles (LNPs) for liver-derived targets such as transthyretin and plasma prekallikrein (KLKB1). As translation expands across hematologic, metabolic, ocular and oncology indications, development is increasingly constrained by the predictability and safety of editing outcomes, delivery-determined biodistribution and exposure time, and immune recognition of bacterial Cas9 orthologs and delivery components. We summarize diagnostic readouts for confirming patient genotype, quantifying on-target editing and expression changes, assessing off-target and structural outcomes using orthogonal assays, and monitoring clonal dynamics and immune responses during long-term follow-up. We also discuss how these readouts interface with CMC controls and regulatory expectations for advanced therapy medicinal products (ATMPs), highlighting the need for fit-for-purpose, standardized testing frameworks in early trials.Keywords
Funding Information
- LEK-AM Pharmaceutical Company Ltd. (2024/ABM/05/KPO/KPOD.07.07-IW.07-0242/24-00)
- Uniwersytet Medyczny w Lodzi (503/0-154-01/503-01-001)
This publication has 190 references indexed in Scilit:
- CRISPR/Cas9-based genome-wide screening for metastasis ability identifies FCGR1A regulating the metastatic process of ovarian cancer by targeting LSP1Journal of Cancer Research and Clinical Oncology, 2024
- CRISPR/Cas9‐based double‐strand oligonucleotide insertion strategy corrects metabolic abnormalities in murine glycogen storage disease type‐IaJournal of Inherited Metabolic Disease, 2023
- Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe2023
- Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU2023
- The X‐linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45–47Journal of Cachexia, Sarcopenia and Muscle, 2023
- CRISPR/Cas9‐HPV‐liposome enhances antitumor immunity and treatment of HPV infection‐associated cervical cancerJournal of Medical Virology, 2022
- Ex Vivo Hepatocyte Reprograming Promotes Homology‐Directed DNA Repair to Correct Metabolic Disease in Mice After TransplantationHepatology Communications, 2019
- Genome‐wide CRISPR‐Cas9 viability screen reveals genes involved in TNF‐α‐induced apoptosis of human umbilical vein endothelial cellsJournal of Cellular Physiology, 2018
- CRISPR/Cas9-mediated gene editing in human tripronuclear zygotesProtein & Cell, 2015
- Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign Genetic ElementsJournal of Molecular Evolution, 2005